| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 03/13/2002 | EP1185284A1 47 human secreted proteins |
| 03/13/2002 | EP1073707A4 A process of making a compound by forming a polymer from a template drug |
| 03/13/2002 | CN1340103A Complex-forming proteins |
| 03/13/2002 | CN1340098A Astrocytes, their preparation and use thereof |
| 03/13/2002 | CN1340059A Peptides |
| 03/13/2002 | CN1339973A Gene therapy for diabetic ischemic disease |
| 03/13/2002 | CN1339604A Gene carrier with glandular relative virus terminal sequence and its use |
| 03/13/2002 | CN1339584A Recombined virus for specific proliferation and high efficiency expression of anti-cancer gene in tumor cells and its constitution method |
| 03/13/2002 | CN1339456A New polypeptide-membrane-spanning protein 35.31 with epidermal growth factor liker repeating functional domain and polynucleotide for encoding such polypeptide |
| 03/12/2002 | US6355775 Transcriptional inhibitor |
| 03/12/2002 | US6355774 Isolated p27 protein |
| 03/12/2002 | US6355622 Use of a melanoma differentiation associated gene (mda-7) for inducing apoptosis of a tumor cell |
| 03/12/2002 | US6355484 Methods and compositions for polypeptides engineering |
| 03/12/2002 | US6355483 Antisense nucleotides for use in the treatment of leukemia |
| 03/12/2002 | US6355480 Nucleotide sequences which code preferential protein for use in the treatment of fertility and cell proliferation defects |
| 03/12/2002 | US6355479 Insect polypeptide for use in the treatment of autoimmune diseases, allergies and cancer |
| 03/12/2002 | US6355463 UDP-N-acetylenolpyruvylglucosamine reductase |
| 03/12/2002 | US6355418 Chimeric oligonucleotides and uses thereof in the identification of antisense binding sites |
| 03/12/2002 | US6355255 Streptococcal C5a peptidase vaccine |
| 03/12/2002 | US6355252 Antiinflammatory agents |
| 03/12/2002 | US6355241 In vivo production and delivery of erythropoietin |
| 03/12/2002 | US6355239 Uses for non-autologous mesenchymal stem cells |
| 03/12/2002 | US6355237 Methods for using the obese gene and its gene product to stimulate hematopoietic development |
| 03/12/2002 | CA2357081A1 Retroviral vectors with foreign-sequence insertion between retroviral primer binding site and retroviral splice donor |
| 03/07/2002 | WO2002018954A2 Inhibition of cmv infection and dissemination |
| 03/07/2002 | WO2002018637A2 Diagnosis and treatment of prostate cancer |
| 03/07/2002 | WO2002018619A2 Nucleic acid constructs including a novel t-cell active promoter, and pharmaceutical compositions and methods utilizing same for regulating t-cell mediated immune response |
| 03/07/2002 | WO2002018609A2 Methods for stable transduction of cells with viral vectors |
| 03/07/2002 | WO2002018593A2 Modulation of fas and fasl expression |
| 03/07/2002 | WO2002018585A2 Packaging of positive-strand rna virus replicon particles |
| 03/07/2002 | WO2002018583A2 Modified polypeptides stabilized in a desired conformation and methods for producing same |
| 03/07/2002 | WO2002018550A1 Selective precipitation of viruses |
| 03/07/2002 | WO2002018548A2 Tyrosine hydroxylase 5' control elements and uses thereof |
| 03/07/2002 | WO2002018545A1 Genetic demonstration of requirement for nkx6.1, nkx2.2 and nkx6.2 in ventral neuron generation |
| 03/07/2002 | WO2002018536A2 Truncated bard1 protein, and its diagnostic and therapeutic uses |
| 03/07/2002 | WO2002018450A1 New cross-linked derivatives of hyaluronic acid |
| 03/07/2002 | WO2002018448A2 Percarboxylated polysaccharides, and a process for their preparation |
| 03/07/2002 | WO2002018444A2 Erbb4 antagonists |
| 03/07/2002 | WO2002018440A1 Anti-angiogenic peptides |
| 03/07/2002 | WO2002018439A2 52991, a human transporter protein and uses therefor |
| 03/07/2002 | WO2002018438A1 Modified proteins, isolated novel peptides, and uses thereof |
| 03/07/2002 | WO2002018435A1 18 human secreted proteins |
| 03/07/2002 | WO2002018409A1 Antisense modulation of hpk/gck-like kinase expression |
| 03/07/2002 | WO2002017968A2 Sensitization of cancer cells to immunoconjugate-induced cell death by transfection with il-13 receptor alpha chain-2 |
| 03/07/2002 | WO2002017949A2 Novel functions for dp214 |
| 03/07/2002 | WO2002017893A2 Sgk2 and sgk3 used as diagnostic and therapeutic targets |
| 03/07/2002 | WO2002017891A2 Method for diagnosing neuronal diseases and for treating primary hemostasis deficiency |
| 03/07/2002 | WO2002017858A2 Role of fosb in bone formation |
| 03/07/2002 | WO2002017852A2 Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers |
| 03/07/2002 | WO2002017713A1 Collagen/polysaccharide bilayer matrix |
| 03/07/2002 | WO2001094420B1 Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury |
| 03/07/2002 | WO2001068856A3 Human transcription factor-like protein and nucleic acids encoding same |
| 03/07/2002 | WO2001068122A3 A method for reversing the immunosuppressive effects of the melanoma inhibitory activity 'mia' |
| 03/07/2002 | WO2001064872A3 Gene 2465: methods and compositions for the diagnosis and treatment of cardiovascular, hepatic and bone disease |
| 03/07/2002 | WO2001062936A3 Bunyaviridal reaper proteins and uses therefor |
| 03/07/2002 | WO2001060983A3 Treatment for bone disorders |
| 03/07/2002 | WO2001060414A3 Genetic modification of the lung as a portal for gene delivery |
| 03/07/2002 | WO2001054716A3 Genetically engineered tumor cell vaccines |
| 03/07/2002 | WO2001051093A3 METHODS OF INCREASING THE GLUCOSE RESPONSIVENESS OF PANCREATIC β-CELLS |
| 03/07/2002 | WO2001040474A3 Compounds and methods for treatment and diagnosis of chlamydial infection |
| 03/07/2002 | WO2001036686A3 Genomic polymorphism for predicting therapeutic response |
| 03/07/2002 | WO2001034774A3 Method for protection of mammalian cells by means of over-expressed g-2/m cell cycle coupler |
| 03/07/2002 | WO2001032888A3 Human transferase molecules |
| 03/07/2002 | WO2001031008A3 Human and rat fgf-20 genes and gene expression products |
| 03/07/2002 | WO2001029220A3 Mage-a12 antigenic peptides and uses thereof |
| 03/07/2002 | WO2001029218A3 Nuclear matrix proteins, polynucleotide sequences encoding them, and their use |
| 03/07/2002 | WO2001019870A3 Secreted soluble alpha2delta-2, alpha2delta-3, alpha2delta-4 calcium channel subunit polypeptides and screening assays using same |
| 03/07/2002 | WO2001016324A3 Methods and compositions of a novel serine protease inhibitor |
| 03/07/2002 | WO2001011086A3 Methods of screening for angiogenesis modulators |
| 03/07/2002 | WO2000073344A9 Monoclonal antibodies, synthetic and biotechnological derivatives thereof acting as ngf-antagonist molecules |
| 03/07/2002 | US20020028925 Hsv viral vector |
| 03/07/2002 | US20020028922 Chemically modified oligonucleotide for site-directed mutagenesis |
| 03/07/2002 | US20020028785 Telomerase resistance; anticancer agents |
| 03/07/2002 | US20020028783 Method of stimulating prosaposin receptor activity |
| 03/07/2002 | US20020028514 Recombinant AAV vector-based transduction system and use of same |
| 03/07/2002 | US20020028513 P element derived vector and methods for its use |
| 03/07/2002 | US20020028498 Genetically engineered nucleotide sequences for use in the treatment of viral disease and tumors |
| 03/07/2002 | US20020028497 Method for producing recombinant adenovirus |
| 03/07/2002 | US20020028495 Deoxyribonuclease II beta proteins and cDNAs |
| 03/07/2002 | US20020028484 Expression vector for use in the treatment and prevention of viral diseases |
| 03/07/2002 | US20020028219 Novel liposome complexes for increased systemic delivery |
| 03/07/2002 | US20020028212 Recombinant viruses coding for a glutamate decarboxylase (gad) activity |
| 03/07/2002 | US20020028207 Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy |
| 03/07/2002 | US20020028198 DNA coding for the protein; useful for a prophylactic or therapeutic agent for hypoglycemia. |
| 03/07/2002 | US20020028194 DNA encoding a transcription unit comprising a transgene linked to expression control sequences, a an adenovirus E3 region, and a modified E4 region containing E4ORF3, and at least one other portion of an adenovirus E4 region |
| 03/07/2002 | US20020028193 Host cell transfected by a vector comprising a DNA sequence encoding a beta 2AR operably linked to a promoter that is functional in said cell. |
| 03/07/2002 | DE10038722A1 Verfahren zur Reduzierung von spezifischen Immunreaktionen A process for the reduction of specific immune responses |
| 03/07/2002 | DE10038111A1 New G protein coupled receptors, useful for diagnosis, treatment and prevention of skin and wound-healing disorders, also related nucleic acid and antibodies |
| 03/07/2002 | CA2424052A1 Packaging of positive-strand rna virus replicon particles |
| 03/07/2002 | CA2421063A1 Methods for stable transduction of cells with viral vectors |
| 03/07/2002 | CA2420944A1 Inhibition of cmv infection and dissemination |
| 03/07/2002 | CA2420902A1 18 human secreted proteins |
| 03/07/2002 | CA2420765A1 Anti-angiogenic peptides |
| 03/07/2002 | CA2420103A1 Modulation of fas and fasl expression |
| 03/07/2002 | CA2420062A1 Erbb4 antagonists |
| 03/07/2002 | CA2419935A1 Collagen/polysaccharide bilayer matrix |
| 03/07/2002 | CA2419851A1 Genetic demonstration of requirement for nkx6.1, nkx2.2 and nkx6.2 in ventral neuron generation |
| 03/07/2002 | CA2419480A1 Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers |
| 03/07/2002 | CA2419472A1 Sgk2 and sgk3 used as diagnostic and therapeutic targets |
| 03/07/2002 | CA2419251A1 Nucleic acid constructs including a novel t-cell active promoter, and pharmaceutical compositions and methods utilizing same for regulating t-cell mediated immune response |